Table 1 Clinical characteristic of 30 newly diagnosed glioblastoma patients.
Factor | Total | Gross total resection group | Supratotal resection group | p-value |
|---|---|---|---|---|
No. of patients | 30 | 23 | 7 | |
Male/female ratio | 13:17 | 11:12 | 2:5 | 0.66 |
Median Tmax/Nave of preoperative Met-PET images (range) | 5.3 (2.8–10.1) | 5.6 (2.8–10.1) | 6.1 (4.0–9.3) | 0.35 |
Median age at surgery, years (range) | 57 (19–78) | 57 (19–78) | 56 (42–76) | 0.69 |
Side of tumor, right/left | 13/17 | 11/12 | 2/5 | 0.36 |
Location of tumor, n | ||||
Frontal | 12 | 10 | 2 | 0.69 |
Temporal | 5 | 4 | 1 | |
Other | 13 | 9 | 4 | |
Preoperative Karnofsky performance score, n (%) | 0.18 | |||
0–60 | 5 (16.7) | 5 (21.7) | 0 | |
70–100 | 25 (83.3) | 18 (78.3) | 7 (100) | |
Postperative Karnofsky performance score, n (%) | 0.31 | |||
0–60 | 3 (10) | 3 (13) | 0 | |
70–100 | 27 (90) | 20 (87) | 7 (100) | |
Median volume of enhanced volume before resection, cc (range) | 18.8 (0.3–101.4) | 19.7 (0.3–101.4) | 14.7 (8.9–40.0) | 0.38 |
Median volume of enhanced volume after resection, cc (range) | 0 | 0 | 0 | – |
Median volume of nonenhanced volume before resection, cc (range) | 58.9 (8.7–185.9) | 59.5 (8.7–185.9) | 29.6 (19.5–82.4) | 0.18 |
Median volume of nonenhanced volume after resection, cc (range) | 28.0 (2.7–103.3) | 33.8 (2.7–103.3) | 12.2 (3.8–31.9) | 0.06 |
No. of patients with methylated MGMT, n (%) | 12 (40%) | 4 (57%) | 8 (35%) | 0.29 |
Median follow-up period for surgery, months (range) | 19.5 (4.6–123.8) | 16.6 (4.6–123.8) | 28.1 (13.1–36.7) | 0.82 |
No. of patients treated with bevacizumab, n (%) | 10 (33%) | 9 (39%) | 1 (14%) | 0.22 |
No. of patients implanted with carmustine wafer, n(%) | 5 (17%) | 5 (22%) | 0 | 0.18 |
No. of patients treated with TTFields therapy, n (%) | 5 (17%) | 2 (8.7%) | 3 (43%) | 0.07 |
No. of patients who underwent awake craniotomy, n (%) | 12 (40%) | 5 (22%) | 7 (100%) | < 0.0001 |
